Related Experiment Video
Updated: Oct 5, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study
Background:
Tyrosine kinase inhibitors (TKIs) have achieved revolutionary results in the treatment of a wide range of tumors, and many studies on this topic continue to be published every year. Some of the published reviews provide great value for us to understand TKIs. However, there is a lack of studies on the knowledge structure, bibliometric analysis, and visualization results in TKIs research.
Objective:
This paper aims to investigate the knowledge structure, hotspots, and trends of evolution of the TKIs research by co-word analysis and literature visualization and help researchers in this field to gain a comprehensive understanding of the current status and trends.
Methods:
We retrieved all academic papers about TKIs published between 2016 and 2020 from the Web of Science. By counting keywords from those papers, we generated the co-word networks by extracting the co-occurrence relationships between keywords, and then segmented communities to identify the subdirections of TKIs research by calculating the network metrics of the overall and local networks. We also mapped the association network topology, including the network within and between TKIs subdirections, to reveal the association and structure among varied subdirections. Furthermore, we detected keyword bursts by combining their burst weights and durations to reveal changes in the focus of TKIs research. Finally, evolution venation and strategic diagram were generated to reveal the trends of TKIs research.
Results:
We obtained 6782 unique words (total frequency 26,175) from 5584 paper titles. Finally, 296 high-frequency words were selected with a threshold of 10 after discussion, the total frequency of which accounted for 65.41% (17,120/26,175). The analysis of burst disciplines revealed a variable number of burst words of TKIs research every year, especially in 2019 and 2020, such as HER2, pyrotinib, next-generation sequencing, immunotherapy, ALK-TKI, ALK rearrangement. By network calculation, the TKIs co-word network was divided into 6 communities: C1 (non-small-cell lung cancer), C2 (targeted therapy), C3 (chronic myeloid leukemia), C4 (HER2), C5 (pharmacokinetics), and C6 (ALK). The venation diagram revealed several clear and continuous evolution trends, such as non-small-cell lung cancer venation, chronic myeloid leukemia venation, renal cell carcinoma venation, chronic lymphocytic leukemia venation. In the strategic diagram, C1 (non-small-cell lung cancer) was the core direction located in the first quadrant, C2 (targeted therapy) was exactly at the junction of the first and fourth quadrants, which meant that C2 was developing; and C3 (chronic myeloid leukemia), C4 (HER2), and C5 (pharmacokinetics) were all immature and located in the third quadrant.
Conclusions:
Using co-word analysis and literature visualization, we revealed the hotspots, knowledge structure, and trends of evolution of TKIs research between 2016 and 2020. TKIs research mainly focused on targeted therapies against varied tumors, particularly against non-small-cell lung cancer. The attention on chronic myeloid leukemia and pharmacokinetics was gradually decreasing, but the focus on HER2 and ALK was rapidly increasing. TKIs research had shown a clear development path: TKIs research was disease focused and revolved around "gene targets/targeted drugs/resistance mechanisms." Our outcomes will provide sound and effective support to researchers, funders, policymakers, and clinicians.
Insights
This study analyzes tyrosine kinase inhibitor (TKI) research from 2016-2020, revealing a focus on non-small-cell lung cancer and targeted therapies. Emerging trends include increased attention on HER2 and ALK targets.
Area of Science:
- Oncology
- Pharmacology
- Bibliometrics
- Data Visualization
Background:
- Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment, with extensive research published annually.
- Existing reviews offer valuable insights, but a comprehensive bibliometric analysis of TKI research knowledge structure and evolution is lacking.
Purpose of the Study:
- To elucidate the knowledge structure, research hotspots, and evolutionary trends in tyrosine kinase inhibitor (TKI) research.
- To provide a comprehensive understanding of the current status and future directions in TKI research through bibliometric analysis and literature visualization.
Main Methods:
- Retrieved and analyzed 5584 TKI-related papers published in the Web of Science from 2016 to 2020.
- Generated co-word networks, community detection, keyword burst analysis, and visualized evolution trends using venation and strategic diagrams.
- Identified research subdirections, associations between them, and shifts in research focus over time.
Main Results:
- Identified 6 research communities: non-small-cell lung cancer (NSCLC), targeted therapy, chronic myeloid leukemia (CML), HER2, pharmacokinetics, and ALK.
- NSCLC emerged as a core research area, while targeted therapy showed development. CML, HER2, and pharmacokinetics were identified as emerging or less mature areas.
- Keyword burst analysis highlighted increasing focus on HER2, pyrotinib, next-generation sequencing, immunotherapy, ALK-TKI, and ALK rearrangement, particularly in 2019-2020.
Conclusions:
- TKI research predominantly focuses on targeted therapies for various cancers, with a significant emphasis on NSCLC.
- Research trends indicate a declining interest in CML and pharmacokinetics, contrasted by a rapidly growing focus on HER2 and ALK.
- The evolution of TKI research follows a pattern of disease focus, revolving around gene targets, targeted drugs, and resistance mechanisms, offering support for researchers and policymakers.
Related Concept Videos
Receptor Tyrosine Kinases
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Therapeutic Drug Monitoring: Overview and Classification
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

